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Abstract
The aim of this study was to analyze trends in 
the listing of non-AIDS-related causes of death 
on the death certificates of adults with HIV/AIDS 
in Brazil. The study analyzed mortality data for 
persons 15 to 69 years of age from 1999 to 2010. 
Standardized mortality odds ratios were used 
to compare mortality from non-AIDS-related 
causes in the group with HIV/AIDS listed on the 
death certificate and in the group without HIV/
AIDS. From 1999 to 2010, there were 6,120,670 
deaths among adults in Brazil. Deaths in the 
HIV group represented 2.2% of the total. Non-
AIDS-related causes, and more specifically car-
diovascular diseases, diseases of the genitouri-
nary system, and non-AIDS-related malignant 
neoplasms increased at higher rates in the group 
with HIV/AIDS listed on the death certificate. 
The results point to a greater increase in mortal-
ity from non-AIDS-related diseases among per-
sons with HIV/AIDS. This finding suggests that 
long contact with HIV and antiretroviral therapy 
play an important role in the occurrence of these 
diseases.
Acquired Immunodeficiency Syndrome; HIV; 
Causes of Death; Death Certificates
Resumo
O objetivo deste estudo foi analisar a tendência 
de menções a causas não relacionadas ao HIV/
AIDS em adultos que viviam com esta doença no 
Brasil. Foram analisados os dados de óbitos de 
pessoas de 15 a 69 anos, ocorridos entre 1999 e 
2010. Utilizaram-se as razões de chance de mor-
talidade padronizadas para comparar a mor-
talidade de causas não associadas ao HIV/AIDS 
entre o grupo em que havia menção ao HIV/
AIDS na declaração de óbito e o grupo em que 
não havia. De 1999 a 2010, ocorreram 6.120.670 
óbitos entre adultos no país. Os óbitos do grupo 
HIV representaram 2,2% do total. Causas não as-
sociadas ao HIV, mais especificamente, doenças 
cardiovasculares, do aparelho genito-urinário 
e neoplasias malignas não associadas ao HIV 
apresentaram crescimento maior no grupo em 
que também havia menção ao HIV/AIDS. Os re-
sultados apontam para um aumento maior da 
mortalidade por doenças não associadas ao HIV 
entre pessoas que viviam com HIV/AIDS. Esse re-
sultado sugere que o longo convívio com o HIV 
e a terapia antirretroviral exercem importante 
papel na ocorrência desses agravos.
Síndrome de Imunodeficiência Adquirida; HIV; 
Causas de Morte; Atestado de Óbito
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Introduction
AIDS mortality indicators in Brazil are monitored 
by the Ministry of Health through deaths notified 
to the Mortality Information System (SIM). These 
indicators are calculated based on the number of 
deaths with the underlying case coded as HIV/
AIDS (codes B20 to B24 in the International Clas-
sification of Diseases, 10th Revision – ICD-10).
According to the Ministry of Health, from 1980 
to 2010 there were 241,469 deaths from AIDS in 
Brazil 1. The AIDS mortality trend in the country 
increased until 1996, when it reached 9.6/100,000 
inhabitants. Starting that year, the mortality 
rate declined and then stabilized around some 
6/100,000 inhabitants.
At the beginning of the AIDS epidemic, the 
most frequently recorded causes of death on the 
death certificate (DC) in persons with HIV/AIDS 
were opportunistic infectious diseases such as: 
tuberculosis; candidiasis and other mycoses; 
toxoplasmosis; pneumonia and other diseases 
of the respiratory system 2; and HIV-related 
neoplasms.
Since Brazil adopted a policy of universal and 
free access to antiretroviral drugs in the public 
healthcare system in 1996, there were changes in 
the morbidity and mortality profile from AIDS in 
the country. There was a sharp drop in mortal-
ity from AIDS in Brazil, along with an increase in 
survival, allowing persons infected with HIV to 
live longer with the virus.
The effects related to the longer co-habitation 
with the virus and with its co-morbidities along 
with the adverse effects of antiretroviral therapy 
made the condition of living with HIV acquire 
similar characteristics to those of other chronic 
and degenerative diseases 3. In addition to the 
traditional causes, cardiovascular diseases, liver 
diseases, diabetes mellitus, viral hepatitis, and 
acute and chronic renal diseases began to be re-
corded more frequently on death certificates of 
persons with HIV/AIDS 4.
Thus, the analysis of AIDS mortality based 
only on the underlying cause of death presents 
limitations. The analysis of underlying cause fails 
to consider other conditions that contribute di-
rectly or indirectly to death and that could help 
understanding the morbidity profile in AIDS 
mortality in the country. 
This study aimed to analyze mortality trends 
due to causes usually considered unrelated to 
HIV/AIDS in deaths among adults from 1999 to 
2010. The study compared deaths in which HIV/
AIDS was listed on the DC (the HIV group) and 
deaths with no mention of HIV/AIDS (the non-
HIV group). The data were analyzed with the 
multiple causes of death approach. That is, in ad-
dition to the underlying cause of death, defined 
as the cause that started the chain of events that 
culminated in death, the study analyzed the re-
lated causes, defined as the antecedent causes 
listed in part I of the death certificate, and the 
causes that contributed to death but were not 
directly associated with the underlying cause, 
listed in part II of the death certificate.
Methods
This was a descriptive trend study analyzing data 
on deaths notified to the SIM, with a case-control 
design.
The study analyzed data on deaths in Brazil 
among individuals 15-69 years of age from 1999 
to 2010, notified to the SIM. The decision was 
made to analyze individuals 15-69 years of age 
for the following reasons: (i) this age bracket in-
cludes nearly 100% of deaths from HIV/AIDS in 
adults in Brazil and (ii) in individuals 70 years 
and older the mortality rate from HIV/AIDS de-
crease considerably when compared to other age 
groups (unpublished data).
Non-nominal individual data on deaths re-
corded in the SIM can be accessed on the web-
site of the Information Technology Department 
of the Unified National Health System (http://
www.datasus.gov.br).
The variables age (15-29, 30-39, 40-49, 50-
59, and 60-69 years), gender (male or female), 
group (HIV or non-HIV), year of death (as a con-
tinuous and categorical variable), region of resi-
dence, race/color (white or other), place of death 
(health service versus other), and multiple causes 
of death (underlying and related causes) were ac-
cessed during the analysis.
The analysis aimed to compare trends in list-
ed non-AIDS-related causes of death in the HIV 
group, consisting of death certificates that men-
tioned HIV/AIDS in any of the sections (codes 
B20 to B24, F02.4, R75, Z11.4, Z20.6, Z21, and 
Z71.7 from the ICD-10) 5 and the non-HIV group, 
consisting of all other deaths.
The study began by describing the deaths 
that occurred during the period and verifying the 
factors associated with listing of HIV/AIDS on the 
DC through logistic regression, with the group 
(HIV or non-HIV) as the dependent variable and 
the following independent variables: gender, age, 
year of death, region of residence, place of death, 
and race/color.
The study then analyzed the trends in non-
AIDS-related causes. Five analyses were per-
formed in which the dependent variables were 
defined according to the presence or absence of 
the following on any line in the DC: (i) cardiovas-
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cular diseases (I00 to I99, except I46); (ii) diabetes 
mellitus (E10 to E14), (iii) diseases of the geni-
tourinary system (N00 to N29); (iv) non-AIDS-
related malignant neoplasms (C00 to C80, except 
sarcoma of Kaposi and malignant neoplasm of 
uterine cervix); and (v) the set of non-AIDS-re-
lated causes, defined as non-AIDS-related ma-
lignant neoplasms (C00 to C80, except sarcoma 
of Kaposi – C46 and malignant neoplasm of cer-
vix uteri – C53), diabetes mellitus (E10 to E14), 
cardiovascular diseases (I00 to I99, except I46), 
diseases of the digestive system (K00 to K93), dis-
eases of the genitourinary system (N00 to N99), 
and external causes (S00 to Y98).
For each condition, the study described fac-
tors associated with its listing on the DC, accord-
ing to group (HIV versus non-HIV), using logistic 
regressions in which the dependent variable was 
the presence or absence of the condition and the 
independent variables were year of death, gen-
der, age bracket, and region of residence.
Finally, the study compared the time trends 
for non-AIDS-related diseases between the HIV 
and non-HIV groups, using the standardized 
mortality odds ratios (SMOR) 6. This statistic is 
used to compare mortality between two groups 
when the data for the denominator are not avail-
able to calculate the mortality rate 4,7,8. To use the 
SMOR, the mortality data should be analyzed as if 
they were data from a case-control study. There-
fore, the current study was structured as follows: 
(i) cases were defined as deaths with the target 
cause mentioned; (ii) controls were defined as 
deaths with no mention of the target cause; (iii) 
the exposed were defined as deaths listing HIV/
AIDS on the DC (HIV group); and (iv) the unex-
posed were defined as those not listing HIV/AIDS 
on the DC (non-HIV group).
To calculate the SMOR, logistic regression 
models were adjusted 9 in which the dependent 
variable was defined as the presence or absence 
of listing of the target cause of death on the DC. 
The selected covariables were year of death, gen-
der, age bracket, and region of residence. The 
difference between the time trends in causes of 
death between the exposed and unexposed was 
tested by adding an interaction term to the logis-
tic regression equation, consisting of the year of 
death and the group (HIV or non-HIV).
The analysis used SPSS 16 for Windows (SPSS 
Inc., Chicago, USA).
Results
From 1999 to 2010, there were 6,120,670 deaths 
among individuals 15-69 years of age in Brazil. 
The majority occurred in men, in individuals 60-
69 years of age, and in residents of the Southeast 
region. The HIV group totaled 136,908 deaths, 
i.e., a mean of 11,400 deaths per year among 
persons with HIV/AIDS and representing 2.2% 
of all deaths in the same period. Deaths in the 
HIV group as compared to the non-HIV group 
showed 11.6 times higher odds of occurring in 
healthcare establishments, 10% higher odds of 
occurring in males, 80% higher odds of occur-
ring in residents of the South as compared to the 
North of Brazil, and 10% higher odds of occurring 
in non-white individuals. Mean age at death was 
39 years in the HIV group and 49 years in the non-
HIV group (Table 1).
In the HIV group, “non-AIDS-related causes” 
were listed in 16.6% of the deaths in 1999. This 
proportion increased to 28.9% in 2010. In the 
non-HIV group, this indicator varied from 76.4% 
to 83.2% in the same period. After adjusting for 
age, gender, and region of residence, the mean 
annual increase in non-AIDS-related causes 
in the HIV group was 3.9% (95%CI: 3.5-4.3; p < 
0.001) and 4.3% in the non-HIV group (95%CI: 
4.3-4.4; p < 0.001). The interaction term was sig-
nificant (SMOR = 1.011; 95%CI: 1.01-1.02) in the 
model, showing that the trends in the mortality 
curves for non-AIDS-related causes were differ-
ent between the two groups (p = 0.001) and that 
the increase was greater in the HIV group. 
Among non-AIDS-related causes, cardio-
vascular diseases showed a greater increase in 
the HIV group compared to the non-HIV group. 
Listing of cardiovascular diseases increased from 
4.3% in 1999 to 8.1% in 2010, with an adjusted 
mean increase of 3.8% per year (95%CI: 3.2-
4.5; p < 0.001) in the HIV group. In the non-HIV 
group, an increase of 0.4% per year was observed 
(95%CI: 0.4-0.5; p < 0.001) and the indicator in-
creased from 33.5% in 1999 to 35% in 2010. The 
interaction term was significant (SMOR = 1.020; 
95%CI: 1.01-1.03) in the model, showing that the 
trends in mortality curves from cardiovascular 
diseases were different between the two groups 
(p = 0.001) and that the increase was greater in 
the HIV group. The odds ratio for listing cardio-
vascular diseases on the DC in 2010 compared 
to 1999 was 1.0 (95%CI: 1.0-1.1) for the non-HIV 
group and 1.7 (95%CI: 1.5-1.9) for the HIV group 
(Figure 1).
In the HIV group, diseases of the genitouri-
nary system were listed in 4.2% of the deaths in 
1999, increasing to 9.8% in 2010. In the non-HIV 
group this proportion increased from 5.2% to 
8.7% in the same period. After adjusting for age, 
gender, and region of residence, the mean annual 
increase in diseases of the genitourinary system 
in the non-HIV group was 4.2% (95%CI: 4.1-4.3; 
p < 0.001) and 5.7% in the HIV group (95%CI: 
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Table 1
Distribution of characteristics and factors associated with listing of HIV/AIDS on the death certifi cate in individuals 15-69 years 
of age in Brazil, 1999-2010, by group.
Variables/Categories Group Total Adjusted OR 
(95%CI)Non-HIV/AIDS HIV/AIDS
n % n %
Age bracket (years)
15-29 855,435 97.4 23,261 2.6 878,696 1.0
30-39 677,324 93.0 50,954 7.0 728,278 2.4 (2.4-2.5)
40-49 1,033,840 96.3 40,013 3.7 1,073,853 1.1 (1.1-1.1)
50-59 1,464,614 98.9 16,941 1.1 1,481,555 0.3 (0.3-0.3)
60-69 1,952,549 99.7 5,739 0.3 1,958,288 0.1 (0.1-0.1)
Gender
Female 3,933,659 97.7 92,813 2.3 4,026,472 1.0
Male 2,050,103 97.9 44,095 2.1 2,094,198 1.1 (1.1-1.1)
Region of residence
North 330,029 98.0 6,664 2.0 336,693 1.0
Northeast 1,417,323 98.7 18,467 1.3 1,435,790 0.7 (0.7-0.7)
Southeast 2,891,979 97.4 75,709 2.6 2,967,688 1.3 (1.3-1.3)
South 941,146 97.1 28,536 2.9 969,682 1.8 (1.8-1.9)
Central-West 403,285 98.2 7,532 1.8 410,817 0.9 (0.9-0.9)
Year of death
1999 468,670 97.9 10,236 2.1 478,906 1.0
2000 472,186 97.8 10,584 2.2 482,770 1.0 (1.0-1.0)
2001 478,038 97.8 10,806 2.2 488,844 1.0 (1.0-1.1)
2002 485,107 97.8 10,973 2.2 496,080 1.0 (1.0-1.1)
2003 489,964 97.8 11,220 2.2 501,184 1.1 (1.0-1.1)
2004 501,015 97.9 11,006 2.1 512,021 1.0 (1.0-1.1)
2005 491,990 97.8 11,064 2.2 503,054 1.1 (1.1-1.1)
2006 499,607 97.8 11,453 2.2 511,060 1.1 (1.1-1.1)
2007 506,312 97.7 11,790 2.3 518,102 1.1 (1.1-1.2)
2008 521,080 97.7 12,302 2.3 533,382 1.2 (1.1-1.2)
2009 529,437 97.6 12,742 2.4 542,179 1.2 (1.1-1.2)
2010 540,356 97.7 12,732 2.3 553,088 1.2 (1.2-1.2)
Race/Color
White 2,903,946 97.7 68,995 2.3 2,972,941 1.0
Other 2,483,904 97.8 56,495 2.2 2,540,399 1.1 (1.0-1.1)
Place of death
Other 1,929,660 99.6 7,011 0.4 1,936,671 1.0
Healthcare establishment 3,995,040 96.9 129,432 3.1 4,124,472 11.6 (11.3-11.9)
95%CI: 95% confi dence interval; OR: odds ratio.
5.0-6.3; p < 0.001). The interaction term was sig-
nificant (SMOR = 1.009; 95%CI: 1.003-1.015) in 
the model, showing that trends in the mortality 
curves from diseases of the genitourinary system 
were different between the two groups (p = 0.005) 
and that the increase was greater in the HIV group. 
The OR for listing of diseases of the genitourinary 
system on the DC in 2010 compared to 1999 was 
1.7 (95%CI: 1.7-1.8) in the non-HIV group and 
2.3 (95%CI: 2.0-2.5) in the HIV group (Figure 2). 
The distribution of diseases of the genitourinary 
system was similar in the two groups, with some 
75% of the listings due to renal failure (ICD-10: 
N17 to N19). 
In the HIV group, non-AIDS-related malig-
nant neoplasms were listed in 1.7% of the deaths 
in 1999, increasing to 4.1% in 2010. In the non-
HIV group this indicator increased from 13.7% to 
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17.1% during the same period. After adjusting for 
age, gender, and region of residence, the mean 
annual increase in non-AIDS-related neoplasms 
was 5.0% in the HIV group (95%CI: 4.1-6.1; p < 
0.001) and 0.5% in the non-HIV group (95%CI: 
2.4-2.6; p < 0.001). The interaction term was sig-
nificant (SMOR = 1.021; 95%CI: 1.01-1.03) in the 
model, showing that trends in the mortality curves 
from non-AIDS-related neoplasms were different 
between the two groups (p = 0.001) and that the 
increase was greater in the HIV group. The OR for 
listing of non-AIDS-related neoplasms on the DC 
in 2010 compared to 1999 was 1.3 (95%CI: 1.3-1.3) 
in the non-HIV group and 2.0 (95%CI: 1.7-2.4) in 
the HIV group (Figure 3). The more frequent list-
ings of non-AIDS-related malignant neoplasms 
in the HIV group, unlike the non-HIV group, were 
for neoplasms of the bronchi and lungs, brain, 
and hepatocellular carcinomas. 
In the HIV group, diabetes mellitus was listed 
in 0.6% of the deaths in 1999, increasing to 1.7% 
in 2010. In the non-HIV group this indicator in-
creased from 6.1% to 8.3% during the same pe-
riod. After adjusting for age, gender, and region 
of residence, the mean annual increase in list-
ing diabetes mellitus was 4.1% in the HIV group 
(95%CI: 2.6-5.5; p < 0.001) and 2.5% in the non-
HIV group (95%CI: 2.4-2.6; p < 0.001). The inter-
action term was not significant (SMOR = 1.011; 
95%CI: 0.997-1.025) in the model, i.e., trends in 
the mortality curves from diabetes mellitus did 
not differ between the two groups (p = 0.112). 
Discussion
The availability of multiple causes of death in 
the Brazilian mortality data since 1999 provides 
an important source of information for a better 
understanding of the mortality pattern among 
persons who lived with HIV/AIDS in Brazil. Thus, 
two similar studies have already been published 
with the aim of assessing the mortality trend from 
non-AIDS-related causes in the country. The first 
study found that among all deaths from 1999 to 
2004 4, the trend in deaths from non-AIDS-re-
lated causes, more specifically from cardiovas-
cular diseases and diabetes mellitus, showed a 
larger increase in the group that also listed HIV/
AIDS on the death certificate. The second study 
showed that among deaths in children from 1999 
to 2007 10, the trend in deaths from non-AIDS-
Figure 1
Odds ratios and 95% confi dence intervals for deaths in individuals 15-69 years of age listing cardiovascular diseases on the 
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Figure 2
Odds ratios and 95% confi dence intervals for deaths in individuals 15-69 years of age listing diseases of the genitourinary 
system on the death certifi cate, by group. Brazil, 1999-2010.
related causes remained stable in the group that 
listed HIV/AIDS on the death certificate, while 
the trend in AIDS-related causes decreased. 
In order to improve and contribute to knowl-
edge on the mortality profile in persons with 
HIV/AIDS in Brazil, the current study sought to 
differentiate itself from the previous studies by 
analyzing deaths among adults and by assessing 
the trend in deaths from diseases of the genito-
urinary system and from non-AIDS-related ma-
lignant neoplasms, in addition to trends in non-
AIDS-related diseases, diabetes mellitus, and 
cardiovascular diseases. 
The study’s results confirm that the mortal-
ity pattern among adults with HIV/AIDS has 
changed since the introduction of highly active 
antiretroviral therapy (HAART). Compared to 
1999, the number of deaths listing non-AIDS-
related causes increased more in the group that 
listed HIV/AIDS on the death certificate when 
compared to the group not listing HIV/AIDS. 
Other authors have reported similar results for 
some time in developed countries 11,12,13,14,15.
Considering that the increase in mean age 
at time of death was significantly greater in the 
HIV group when compared to the non-HIV group 
(data not published), it is believed that the aging 
resulting from the increased survival of patients 
with AIDS is an important factor in the chang-
ing mortality pattern of the adult population with 
HIV. However, it is also believed that HAART and 
the long contact with HIV are contributing to the 
increase in deaths from causes not related to HIV/
AIDS among persons with HIV/AIDS, since these 
causes displayed a significantly higher propor-
tional increase in the HIV group when compared 
to the non-HIV group during the study period, 
even after adjusting for age.
The results also suggest that among non-
AIDS-related causes, the trend in the mortality 
curves from cardiovascular diseases is increas-
ing significantly more in the HIV group when 
compared to the non-HIV group. These results 
agree with findings by other authors showing an 
increase in deaths from cardiovascular diseases 
in persons with HIV/AIDS since the introduction 
of HAART 13,16,17.
In addition to the high prevalence of risk fac-
tors for cardiovascular diseases such as smoking, 
arterial hypertension, and elevated triglycerides 
and VHDL cholesterol among persons with HIV/
AIDS 18, studies suggest that HAART and the 
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chronic inflammation characterizing HIV infec-
tion are associated with greater risk of cardio-
vascular diseases in persons with HIV/AIDS 19,20. 
Some studies have shown greater risk of cardio-
vascular events in persons with HIV/AIDS and 
on HAART as compared to those without treat-
ment 21,22. Among the antiretroviral drugs, the 
protease inhibitors 23, lopinavir-ritonavir or in-
dinavir 24, and regimens containing abacavir or 
didanosine 25 show greater risk of cardiovascular 
diseases. 
In view of the population aging of persons 
with HIV/AIDS, prolonged use of HAART, long 
contact with the virus, and high prevalence of risk 
factors for cardiovascular diseases in this popula-
tion, several authors have discussed specific ap-
proaches to screen and diagnose cardiovascular 
diseases in persons with HIV/AIDS 26. However, 
more research is needed to better elucidate the 
relationship between HIV, HAART, and cardio-
vascular diseases. The current recommendations 
for avoiding cardiovascular diseases in persons 
with HIV/AIDS are still similar to the recommen-
dations for the general population. Strategies to 
decrease the risk of cardiovascular diseases in 
persons with HIV/AIDS should be incorporated 
into the primary care for these patients.
The trends in mortality curves from non-
AIDS-related malignant neoplasms also differ 
between the two groups; as demonstrated 13,16, 
the increase is greater in the HIV group. Although 
the incidence of AIDS-related neoplasms has 
decreased since the introduction of HAART, it is 
known that non-AIDS-related malignant neo-
plasms are currently important causes of mortal-
ity in persons with HIV/AIDS in the developed 
countries 13,14. The increase in the proportion of 
deaths from non-AIDS-defining malignant neo-
plasms in persons with HIV/AIDS can be attrib-
uted to: (i) aging of the HIV-infected population; 
Figure 3
Odds ratios and 95% confi dence intervals for deaths in individuals 15-69 years of age listing non-AIDS-related malignant 
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(ii) presence of risk factors such as smoking and 
alcohol abuse, which present high prevalence 
among persons with HIV/AIDS 27; (iii) immuno-
suppression caused by HIV 28, (iv) co-infection 
with oncogenic viruses 29; and (v) the probable 
oncogenic effect of HAART 30. In agreement with 
other studies, 30,31, malignant neoplasms of the 
lungs and hepatocellular carcinoma were more 
frequent among the HIV group. Preventive mea-
sures against these neoplasms could include, for 
example, cessation of risk behaviors such as alco-
holism and smoking, improved screening and di-
agnosis of neoplasms in persons with HIV/AIDS, 
screening for infection with hepatitis B and hepa-
titis C virus, and vaccination of the adult popula-
tion against hepatitis B. 
Diseases of the genitourinary system also 
show a higher proportional increase in the HIV 
group when compared to the non-HIV group, 
corroborating findings by other authors 32,33. 
HIV-related nephropathies can be caused by 
HIV itself or by the adverse effect of nephrotoxic 
drugs, leading to altered renal function due to the 
induction of metabolic vasculopathy and direct 
renal injury 3. This would explain the significantly 
greater increase in diseases of the genitourinary 
system in the HIV group. Among these diseases, 
renal failure (codes N17 to N19 of ICD-10) play 
an important role in the increased mortality in 
the HIV group, since when removing this disease 
from the analysis of diseases of the genitourinary 
system, the difference between the curves in the 
two groups disappears.
This study demonstrated that listing of dia-
betes mellitus on death certificates has increased 
over time in the HIV and non-HIV groups. The 
increase in mortality from diabetes mellitus in 
the two groups agrees with studies that show an 
increase in incidence of diabetes mellitus, in the 
proportion of hospital admission for diabetes 
mellitus, and in the proportion of deaths from 
diabetes mellitus in the Brazilian population 34. 
Since persons with HIV/AIDS are exposed to 
the same risk factors as the general population, 
plus additional metabolic factors specific to HIV 
and HAART that increase the risk of developing 
diabetes mellitus, it was expected that mortality 
from diabetes would increase at a significantly 
higher rate in the HIV group as compared to 
the non-HIV group. However, the current study 
showed no difference between these mortality 
curves. A possible explanation is that persons 
with diabetes mellitus usually die from chronic 
complications of the disease such as cardiovas-
cular diseases and renal failure, which end up 
being recorded as the causes of these deaths. 
And since listing of cardiovascular diseases and 
renal failure on death certificates increased 
more in the HIV group compared to the non-HIV 
group, diabetes mellitus may also be increasing 
at a higher rate in the HIV group compared to the 
non-HIV group. 
The study presents some limitations. First, 
there are inherent obstacles to the use of data 
from death certificates, since completing the cer-
tificates depends exclusively on the assessment 
of the attesting physician, which may vary ac-
cording to school and region, or even according 
to the understanding of which causes should be 
listed 35. In addition, since the study only ana-
lyzed vital statistics, it was not possible to assess 
factors associated with greater mortality risk 
such as HAART, date of diagnosis, CD4+ count, 
and presence of other risk factors such as injec-
tion drug use, smoking, and alcoholism. 
Another limitation relates to the definition of 
HIV group used in this study. The HIV group only 
included persons whose DC mentioned HIV/
AIDS. However, a study in Rio de Janeiro estimat-
ed that some 30% of deaths in patients known 
to be HIV-positive failed to mention HIV/AIDS 
anywhere on the DC 36, suggesting that the HIV 
group is underestimated in this study. However, 
as mentioned by Pacheco et al. 4 in their article’s 
discussion, the mortality rate for deaths that 
mentioned HIV/AIDS on the DC remained stable 
over time, in agreement with the mortality data 
on AIDS in Brazil. Thus, since the study’s analysis 
focused on year of death, it is believed that the 
underestimation of deaths in the HIV group does 
not invalidate the results.
In conclusion, this study’s results point to a 
greater increase in mortality from cardiovascular 
diseases, diseases of the genitourinary system, 
and non-AIDS-related malignant neoplasms 
among persons with HIV/AIDS when compared 
to non-HIV-infected persons. These results sug-
gest that long contact with HIV and HAART play 
an important role in the occurrence of these 
diseases. Thus, it is indispensable that the clini-
cal management of these patients includes the 
prevention, diagnosis, and treatment of such dis-
eases. As other authors have recommended, the 
results presented here reinforce the need to in-
tegrate the care for persons with HIV/AIDS with 
other public health programs 4.
Fazito E et al.1652
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Resumen
Este estudio tiene como objetivo analizar la tendencia 
en la mención de las causas de muerte no relacionadas 
con el VIH/ SIDA, en los certificados de defunción de los 
adultos que vivían con el VIH/SIDA en Brasil. Se estu-
diaron con detenimiento los datos de las muertes de los 
adultos brasileños entre 1999 y 2010, además, se utiliza-
ron las odds ratios estandarizadas de mortalidad para 
comparar las causas de muerte entre las personas que 
vivían con el VIH/SIDA y las personas que no vivían con 
la enfermedad. De 1999 a 2010, se produjeron 6.120.670 
muertes de adultos en Brasil. En un 2,2% del total de 
muertes en adultos, el VIH/SIDA figuraba mencionado 
en el certificado de defunción. Las causas no asociadas 
al VIH/SIDA, más específicamente, las enfermedades 
cardiovasculares, las enfermedades genitourinarias y 
neoplasias malignas, presentan un aumento de mayor 
intensidad en la frecuencia respecto a las que se enu-
meran como causas de muerte para quienes también 
vivían con el VIH.
Síndrome de Inmunodeficiencia Adquirida; VIH; 
Causas de Muerte; Certificado de Defunción
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